<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309566</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-BEQ-EET-002-V.01</org_study_id>
    <nct_id>NCT03309566</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir</brief_title>
  <official_title>Bioequivalence Study of Efavirenz, Emtricitabine and Tenofovir in Healthy Volunteers, After Administering a Single Dose of a Fixed Dose Combination of the Test Formulation With Respect to the Reference Product, Atripla ® From Gador S.A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorio Elea S.A.C.I.F. y A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorio Elea S.A.C.I.F. y A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study of two formulations containing a fixed dose combination of 600 mg
      Efavirenz, 200 mg Emtricitabine and 300 mg Tenofovir Disproxyl Fumarate in coated tablets
      under a single-dose, two-way crossover design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2016</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, two-way crossover.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>192 hours</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>192 hours</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>192 hours</time_frame>
    <description>Drug related toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test - Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference - Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz, tenofovir disoproxil fumarate and emtricitabine</intervention_name>
    <description>Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.</description>
    <arm_group_label>Test - Reference</arm_group_label>
    <arm_group_label>Reference - Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male subjects between 18 and 55 years. Subjects with body mass index (BMI) between 19 and
        27 kg / m². Subjects whose complementary tests (ECG, blood and urine) are within normal and
        / or clinically insignificant according to the judgment of the investigator.

        Subjects with systolic blood pressure between 110 mmHg and 139 mmHg; diastolic pressure
        between 70 mmHg and 89 mmHg; heart rate between 50 and 90 beats per minute.

        Subjects who signed informed consent.

        Exclusion Criteria:

        Background of clinically significant allergies (except untreated asymptomatic seasonal
        allergies), drug hypersensitivity and / or hypersensitivity to any component of the
        formulations studied.

        Drop of more than 20 mmHg in systolic blood pressure or more than 10 mmHg diastolic
        pressure in the first 3 minutes of postural change.

        Active smoker more than 10 cigarettes / day. Pregnant or lactating women. Current clinical
        evidence of severe digestive disorders, surgery of the digestive tract (except
        appendectomy).

        Current clinical evidence of kidney disease. Current evidence of liver disorders Current
        clinical evidence of respiratory and heart diseases. The presence of diabetes mellitus,
        thyroid dysfunction or other endocrine disorder.

        Evidence of gastroduodenal disease. Current presence of any malignancy. History of abuse or
        addiction to drugs or alcohol during the past three years. Participation in a clinical
        trial within the last three months. Use of any drug within fourteen days before the start
        of the study. Subject donated or suffered blood loss during the last twelve weeks before
        the start of the study, or intends to donate blood within three months of the completion of
        the study.

        Excessive drinking of tea, cocoa, mate, coffee and / or beverages containing caffeine (&gt; 5
        cups / day) or wine (&gt; 0.5 L / day) or alcohol (&gt; 50 ml / day).

        ECG abnormalities. Positive serology for HIV, hepatitis B or hepatitis C.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María C Fritz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DominguezLab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DominguezLab</name>
      <address>
        <city>Paraná</city>
        <state>Entre Ríos</state>
        <zip>3102</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

